| Title |
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
|
|---|---|
| Published in |
Infection and Drug Resistance, September 2018
|
| DOI | 10.2147/idr.s150447 |
| Pubmed ID | |
| Authors |
Lindsay A Petty, Oryan Henig, Twisha S Patel, Jason M Pogue, Keith S Kaye |
| Abstract |
There has been a worldwide increase in infections caused by drug-resistant Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE). Meropenem-vaborbactam, a carbapenem antibiotic and novel boronic acid-based beta-lactamase inhibitor, is a fixed-dose combination product with potent in vitro activity against Enterobacteriaceae that are Klebsiella pneumoniae carbapenemase producers. Meropenem-vaborbactam has been studied in two Phase III trials, Targeting Antibiotic Non-susceptible Gram-negative Organisms (TANGO)-I and TANGO-II. TANGO-I was a multicenter, international Phase III, randomized, double-blind, double-dummy, active-control trial to evaluate the efficacy and safety of meropenem-vaborbactam for the treatment of complicated urinary tract infection, including acute pyelonephritis. Among patients with complicated urinary tract infection and growth of a baseline pathogen, meropenem-vaborbactam was determined to be superior to piperacillin-tazobactam based on the composite outcome of symptom improvement or resolution and microbial eradication at the end of intravenous therapy. TANGO-II was a multicenter, international, Phase III, randomized, prospective, open-label, comparative trial to evaluate the efficacy and safety of meropenem-vaborbactam vs best available therapy for CRE infections. Treatment with meropenem-vaborbactam resulted in higher rates of clinical cure at the end of therapy (64.3%vs 33.3%, P=0.04). Additionally, 28-day all-cause mortality was 17.9% in the meropenem-vaborbactam group compared to 33.3% in the best available therapy group, a relative risk reduction of 46.5% (P=0.03). In addition to meropenem-vaborbactam, three other agents with activity against CRE are in late-stage development: imipenem-relebactam, plazomicin, and cefiderocol. The data from Phase II and III studies will help to further define the role of these agents. Overall, the recent approval of meropenem-vaborbactam and the active pipeline for other agents with broad Gram-negative activity are encouraging developments on the CRE therapeutic front. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 13% |
| United Kingdom | 1 | 13% |
| United States | 1 | 13% |
| Unknown | 5 | 63% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 63% |
| Practitioners (doctors, other healthcare professionals) | 3 | 38% |
Mendeley readers
The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 156 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 12% |
| Student > Ph. D. Student | 15 | 10% |
| Student > Master | 15 | 10% |
| Other | 14 | 9% |
| Researcher | 13 | 8% |
| Other | 22 | 14% |
| Unknown | 59 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 9% |
| Biochemistry, Genetics and Molecular Biology | 13 | 8% |
| Immunology and Microbiology | 12 | 8% |
| Agricultural and Biological Sciences | 5 | 3% |
| Other | 12 | 8% |
| Unknown | 68 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2020.
All research outputs
#5,872,302
of 23,308,124 outputs
Outputs from Infection and Drug Resistance
#205
of 1,730 outputs
Outputs of similar age
#101,278
of 336,294 outputs
Outputs of similar age from Infection and Drug Resistance
#11
of 80 outputs
Altmetric has tracked 23,308,124 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,730 research outputs from this source. They receive a mean Attention Score of 4.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,294 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.